SEQUENCE LISTING

<110> Allysta Pharmaceuticals, Inc.
Hsu, Henry

<120> Adiponectin Peptidomimetics for Treating Ocular Disorders

<130> ALLY002.CIPPCT

<140> Unassigned
<141> 2018-08-07

<150> US 15/676,968
<151> 2017-08-14

<160> 7

<170> PatentIn version 3.5

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 may be Asn or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (1)..(11)
<223> provided that at least one of positions 1, 4, 7 or 10 is a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 may be Gly or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 may be Tyr or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> when Xaa at position 10 or Xaa at position 11 is a C-terminal amino acid, said C-terminal amino acid is optionally amidated

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 may be Tyr or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)

<223> Xaa at position 11 may be absent, bAla or bAlaNH2

<400> 1

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa
1 5 10

<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is Asn or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (1)..(10)
<223> provided that at least one of Xaa at position 1, Xaa at position 4, Xaa at position 7 or Xaa at position 10 is a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (1)..(10)
<223> wherein the C-terminal amino acid is optionally amidated

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Gly or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 is Tyr or a non-natural amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is Tyr or a non-natural amino acid

<400> 2

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa
1 5 10

<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is D-Asn

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Nva

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 is D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is D-Ser

<400> 3

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa
1 5 10

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is D-Asn

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Nva

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 is D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is D-Ser

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa at position 11 is bAla

<400> 4

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa
1 5 10

<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is D-Asn

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Nva

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 is D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is D-Ser

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa at position 11 is bAlaNH2

<400> 5

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa
1 5 10

<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is D-Asn

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Nva

<220>
<221> MISC_FEATURE
<222> (7)..(7)

<223> Xaa at position 7 is D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is D-Ser-NH2

<400> 6

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa
1   5   10

<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa at position 1 is D-Asn

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa at position 4 is Nva

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa at position 7 is D-Ser

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa at position 10 is D-Ser

<400> 7

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa His Pro
1   5   10